Can partial splenic embolization be a promising treatment for hypersplenism–related thrombocytopenia in oncological patients requiring systemic chemotherapy: a retrospective analysis
El Sammak, D., Allam, H., M. Abdelhay, R. (2021). Can partial splenic embolization be a promising treatment for hypersplenism–related thrombocytopenia in oncological patients requiring systemic chemotherapy: a retrospective analysis. EKB Journal Management System, 27(5), 962-972. doi: 10.21608/zumj.2021.50403.2020
Dena Abd El Aziz El Sammak; Hala Mohammed Allam; Rabab M. Abdelhay. "Can partial splenic embolization be a promising treatment for hypersplenism–related thrombocytopenia in oncological patients requiring systemic chemotherapy: a retrospective analysis". EKB Journal Management System, 27, 5, 2021, 962-972. doi: 10.21608/zumj.2021.50403.2020
El Sammak, D., Allam, H., M. Abdelhay, R. (2021). 'Can partial splenic embolization be a promising treatment for hypersplenism–related thrombocytopenia in oncological patients requiring systemic chemotherapy: a retrospective analysis', EKB Journal Management System, 27(5), pp. 962-972. doi: 10.21608/zumj.2021.50403.2020
El Sammak, D., Allam, H., M. Abdelhay, R. Can partial splenic embolization be a promising treatment for hypersplenism–related thrombocytopenia in oncological patients requiring systemic chemotherapy: a retrospective analysis. EKB Journal Management System, 2021; 27(5): 962-972. doi: 10.21608/zumj.2021.50403.2020

Can partial splenic embolization be a promising treatment for hypersplenism–related thrombocytopenia in oncological patients requiring systemic chemotherapy: a retrospective analysis

Zagazig University Medical Journal
Article 660, Volume 27, Issue 5, September 2021, Page 962-972  XML PDF (979.68 K)
Document Type: Original Article
DOI: 10.21608/zumj.2021.50403.2020
View on SCiNiTO View on SCiNiTO
Authors
Dena Abd El Aziz El Sammak email 1; Hala Mohammed Allam2; Rabab M. Abdelhay1
1Radiology department zagazig university sharkia Egypt
2Internal Medicine, Zagazig University
Abstract
Background: PSE has been safely used to improve hypersplenism–related thrombocytopenia by reducing the splenic volume using conventional transarterial superselective embolization technique. PSE provides an increase in hematologic indices to facilitate initiation and continuation of SC in oncological patients who are not surgical candidates and for whom splenectomy is contraindicated.
OBJECTIVE: The aim of this study is to evaluate 1ry, 2ry end points, technical parameters, outcomes and complications of PSE in oncological patients with hypersplenism-related thrombocytopenia requiring SC.
METHODS: This retrospective study comprised 24 oncological patients (18 males and 6 females; their ages ranged 35–70 years old), they underwent PSE for correcting thrombocytopenia in order to initiate (n=6) or continue (n=18) their optimally dosed SC. The 1ry endpoint was the achievement of a platelet count >130×〖10〗^9/L and the 2ry endpoint was the initiation or continuation of SC.
RESULTS: Mean platelet count prior to PSE was 69.08 ± 3.54 ×109/L (range 62–75×109/L).The percentage of splenic necrosis was estimated by angiography, mean post-PSE splenic infarction percentage was 58.33 ± 8.16 %. Mean platelet counts at days 10, 20 and 30 post-PSE were 273.58±77.30×109/L, 218.54±60.06×109/L and 157.16±44.90×109/L, respectively (P
Keywords
partial splenic embolization; hypersplenism; thrombocytopenia; systemic chemotherapy
Statistics
Article View: 295
PDF Download: 233